ConductScience.org, home

Paper39770490

Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights.

Jovalekic A and 15 others. Pharmaceuticals (Basel), 2024. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights. Papers, record 39770490. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39770490

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights.
PubMed
Journal
Pharmaceuticals (Basel)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.67, provisional
iCite
Revised in PubMed
2025-01-15
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jovalekic AAleksandar
2Bullich SSantiago
3Roé-Vellvé NNúria
4Kolinger GDGuilherme Domingues
5Howard LRLorelei R
6Elsholz FFloriana
7Lagos-Quintana MMariana
8Blanco-Rodriguez BBeatriz
9Pérez-Martínez EEsther
10Gismondi RRossella
11Perrotin AAudreyhttps://orcid.org/0009-0003-8398-880X
12Chapleau MMarianne
13Keegan RRichard
14Mueller AAndrehttps://orcid.org/0000-0001-7271-9303
15Stephens AWAndrew W
16Koglin NNormanhttps://orcid.org/0000-0001-7583-8201

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References90

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139366841Alzheimer's disease biomarkers and the tyranny of treatment.EBioMedicine2024https://conductscience.org/library/papers/39366841PubMed
237966285Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.N Engl J Med2023https://conductscience.org/library/papers/37966285PubMed
331564456Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.Cell2019https://conductscience.org/library/papers/31564456PubMed
425824567Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.Alzheimers Dement2015https://conductscience.org/library/papers/25824567PubMed
518191617Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.Lancet Neurol2008https://conductscience.org/library/papers/18191617PubMed
630938796Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.JAMA2019https://conductscience.org/library/papers/30938796PubMed
737357283Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe.J Prev Alzheimers Dis2023https://conductscience.org/library/papers/37357283PubMed
829653606NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.Alzheimers Dement2018https://conductscience.org/library/papers/29653606PubMed
931594684Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project.Alzheimers Dement2019https://conductscience.org/library/papers/31594684PubMed
1029186280FACEHBI: A Prospective Study of Risk Factors, Biomarkers and Cognition in a Cohort of Individuals with Subjective Cognitive Decline. Study Rationale and Research Protocols.J Prev Alzheimers Dis2017https://conductscience.org/library/papers/29186280PubMed
1129282327Practice guideline update summary: Mild cognitive impairment [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.Neurology2018https://conductscience.org/library/papers/29282327PubMed
1238512444Comparison of consistency in centiloid scale among different analytical methods in amyloid PET: the CapAIBL, VIZCalc, and Amyquant methods.Ann Nucl Med2024https://conductscience.org/library/papers/38512444PubMed
1335618838Performance of plasma phosphorylated tau 181 and 217 in the community.Nat Med2022https://conductscience.org/library/papers/35618838PubMed
1435389071Quantification of amyloid PET for future clinical use: a state-of-the-art review.Eur J Nucl Med Mol Imaging2022https://conductscience.org/library/papers/35389071PubMed
1533184233Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals.Neurology2021https://conductscience.org/library/papers/33184233PubMed
1635235702Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice.Alzheimers Dement2023https://conductscience.org/library/papers/35235702PubMed
1725741488Beta-amyloid imaging with florbetaben.Clin Transl Imaging2015https://conductscience.org/library/papers/25741488PubMed
1825443857The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.Alzheimers Dement2015https://conductscience.org/library/papers/25443857PubMed
1929107051Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study.Alzheimers Dement2018https://conductscience.org/library/papers/29107051PubMed
2036419238A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting.Alzheimers Dement2023https://conductscience.org/library/papers/36419238PubMed

See all 90 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42720909Amyloid-β PET Radioligands in Alzheimer's Disease: From Plaque Detection to Biomarker-Guided Patient Stratification and Therapeutic Monitoring.Mol Diagn Ther2026https://conductscience.org/library/papers/42720909PubMed
41803942In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences.Alzheimers Res Ther2026https://conductscience.org/library/papers/41803942PubMed
41238774Concordance between amyloid PET and CSF biomarkers in clinical setting: a cross-platform comparison and in-depth analysis of discordant cases.Sci Rep2025https://conductscience.org/library/papers/41238774PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39770490

GET https://conductscience.org/api/papers/v1/39770490/references?page=2